MASS Quote, Financials, Valuation and Earnings

Repligen has a net margin of -103.33% compared to 908 Devices's net margin of 3.45%. 908 Devices's return on equity of -12.31% beat Repligen's return on equity of -1.16%.

908 Devices has a consensus price target of $5.50, signalling downside risk potential of -17.54%. On the other hand Repligen has an analysts' consensus of $180.82 which suggests that it could grow by 51%. Given that Repligen has higher upside potential than 908 Devices, analysts believe Repligen is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Repligen has a beta of 1.110, suggesting its more volatile than the S&P 500 by 10.976%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $11.8M, which are smaller than Repligen quarterly revenues of $169.2M. 908 Devices's net income of $43.6M is higher than Repligen's net income of $5.8M. Notably, 908 Devices's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 3.77x versus 10.36x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -103.33% compared to 908 Devices's net margin of -2201.34%. 908 Devices's return on equity of -12.31% beat VolitionRX's return on equity of --.

908 Devices has a consensus price target of $5.50, signalling downside risk potential of -17.54%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than 908 Devices, analysts believe VolitionRX is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $11.8M, which are larger than VolitionRX quarterly revenues of $246.4K. 908 Devices's net income of $43.6M is higher than VolitionRX's net income of -$5.4M. Notably, 908 Devices's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 3.77x versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -103.33% compared to 908 Devices's net margin of -2828.67%. 908 Devices's return on equity of -12.31% beat Catheter Precision's return on equity of -137.84%.

908 Devices has a consensus price target of $5.50, signalling downside risk potential of -17.54%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 788.89%. Given that Catheter Precision has higher upside potential than 908 Devices, analysts believe Catheter Precision is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $11.8M, which are larger than Catheter Precision quarterly revenues of $143K. 908 Devices's net income of $43.6M is higher than Catheter Precision's net income of -$4M. Notably, 908 Devices's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 3.77x versus 2.58x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -103.33% compared to 908 Devices's net margin of 0.18%. 908 Devices's return on equity of -12.31% beat Xtant Medical Holdings's return on equity of -26.62%.

908 Devices has a consensus price target of $5.50, signalling downside risk potential of -17.54%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than 908 Devices, analysts believe Xtant Medical Holdings is more attractive than 908 Devices.

908 Devices has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

908 Devices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 908 Devices pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

908 Devices quarterly revenues are $11.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. 908 Devices's net income of $43.6M is higher than Xtant Medical Holdings's net income of $58K. Notably, 908 Devices's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 908 Devices is 3.77x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.